Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Synodos for NF2 Consortium, Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN.

PLoS One. 2018 Jun 13;13(6):e0197350. doi: 10.1371/journal.pone.0197350. eCollection 2018.

2.

Cellular prion protein (PrPC) in the development of Merlin-deficient tumours.

Provenzano L, Ryan Y, Hilton DA, Lyons-Rimmer J, Dave F, Maze EA, Adams CL, Rigby-Jones R, Ammoun S, Hanemann CO.

Oncogene. 2017 Nov 2;36(44):6132-6142. doi: 10.1038/onc.2017.200. Epub 2017 Jul 10.

PMID:
28692055
3.

A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.

Gehlhausen JR, Hawley E, Wahle BM, He Y, Edwards D, Rhodes SD, Lajiness JD, Staser K, Chen S, Yang X, Yuan J, Li X, Jiang L, Smith A, Bessler W, Sandusky G, Stemmer-Rachamimov A, Stuhlmiller TJ, Angus SP, Johnson GL, Nalepa G, Yates CW, Wade Clapp D, Park SJ.

Hum Mol Genet. 2019 Feb 15;28(4):572-583. doi: 10.1093/hmg/ddy361.

PMID:
30335132
4.

AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.

Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, Chaudhury AR, Kulp S, Chen CS, Chang LS, Welling DB, Jacob A.

Neuro Oncol. 2011 Sep;13(9):983-99. doi: 10.1093/neuonc/nor072. Epub 2011 Jul 21.

5.

Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.

Wong HK, Shimizu A, Kirkpatrick ND, Garkavtsev I, Chan AW, di Tomaso E, Klagsbrun M, Jain RK.

Neoplasia. 2012 Feb;14(2):84-94.

6.

FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.

Licciulli S, Maksimoska J, Zhou C, Troutman S, Kota S, Liu Q, Duron S, Campbell D, Chernoff J, Field J, Marmorstein R, Kissil JL.

J Biol Chem. 2013 Oct 4;288(40):29105-14. doi: 10.1074/jbc.M113.510933. Epub 2013 Aug 19.

7.

Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.

James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, Gusella JF, Stemmer-Rachamimov AO, Ramesh V.

Mol Cancer Res. 2012 May;10(5):649-59. doi: 10.1158/1541-7786.MCR-11-0425-T. Epub 2012 Mar 16.

8.

An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.

Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J.

Cancer Res. 2017 Sep 15;77(18):5026-5038. doi: 10.1158/0008-5472.CAN-16-2834. Epub 2017 Jul 20.

9.

Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.

Burns SS, Chang LS.

Methods Mol Biol. 2016;1427:59-72. doi: 10.1007/978-1-4939-3615-1_4.

PMID:
27259921
10.

Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.

Petrilli AM, Fernández-Valle C.

Methods Mol Biol. 2018;1739:161-173. doi: 10.1007/978-1-4939-7649-2_11.

PMID:
29546707
11.

Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.

Dickinson PJ, Surace EI, Cambell M, Higgins RJ, Leutenegger CM, Bollen AW, LeCouteur RA, Gutmann DH.

Vet Pathol. 2009 Sep;46(5):884-92. doi: 10.1354/vp.08-VP-0251-D-FL. Epub 2009 May 9.

PMID:
19429976
12.

Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.

Petrilli A, Bott M, Fernández-Valle C.

Oncotarget. 2013 Dec;4(12):2354-65.

13.

The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges.

Wang B, Cui Z, Zhong Z, Sun Y, Yang GY, Sun Q, Bian L.

Mol Carcinog. 2016 Dec;55(12):2268-2277. doi: 10.1002/mc.22467. Epub 2016 Feb 3.

PMID:
26840621
14.

The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.

Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder E, Sharma V, Ercolano E, Hilton D, Taiwo I, Barczyk M, Hanemann CO.

Oncogene. 2016 Jun 30;35(26):3443-53. doi: 10.1038/onc.2015.404. Epub 2015 Nov 9.

15.

Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.

Bassiri K, Ferluga S, Sharma V, Syed N, Adams CL, Lasonder E, Hanemann CO.

EBioMedicine. 2017 Feb;16:76-86. doi: 10.1016/j.ebiom.2017.01.020. Epub 2017 Jan 18.

16.

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF, Ramesh V.

Mol Cell Biol. 2009 Aug;29(15):4250-61. doi: 10.1128/MCB.01581-08. Epub 2009 May 18.

17.

Neurofibromatosis 2.

Baser ME, R Evans DG, Gutmann DH.

Curr Opin Neurol. 2003 Feb;16(1):27-33. Review.

PMID:
12544854
18.

Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas.

Kimura Y, Saya H, Nakao M.

Neuropathology. 2000 Sep;20(3):153-60. Review.

PMID:
11132929
19.

Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.

Fuse MA, Plati SK, Burns SS, Dinh CT, Bracho O, Yan D, Mittal R, Shen R, Soulakova JN, Copik AJ, Liu XZ, Telischi FF, Chang LS, Franco MC, Fernandez-Valle C.

Mol Cancer Ther. 2017 Nov;16(11):2387-2398. doi: 10.1158/1535-7163.MCT-17-0417. Epub 2017 Aug 3.

20.

Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.

Yang C, Asthagiri AR, Iyer RR, Lu J, Xu DS, Ksendzovsky A, Brady RO, Zhuang Z, Lonser RR.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4980-5. doi: 10.1073/pnas.1102198108. Epub 2011 Mar 7.

Supplemental Content

Support Center